Resinco Capital Partners to enter the Cannabis Pharma Sector in search of New Investment Opportunities

VANCOUVER, British Columbia, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Resinco Capital Partners Inc. (CSE:RIN) (the "Company" or "Resinco") announces that it has commenced its due diligence and research procedures in search of new investment opportunities in the growing Cannabis Pharmaceutical Sector to diversify and strengthen its existing portfolio. Resinco's management team and board of directors will remain the same as it pursues new Cannabis Pharma opportunities.

Resinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining positions in early stage investment opportunities that adequately reflect the risk profile. The initiative by the company to enter the growing Cannabis Pharma space is a reflection of its focus on innovative new markets. The company is moving forward to explore exciting new opportunities in the Cannabis Pharma Sector and hopes to find additional investments in the near future.

Website:

www.resincocp.com

Cannabis and Legalization Procedures in Canada

The Cannabis Act, also known as Bill C-45 is the law that will come into place on October 17^th 2018 that will legalize the recreational use of cannabis nationwide in Canada. The act itself was passed by the House of Commons in late November 2017 and then the Senate of Canada in June 2018. In the US, cannabis is already legal in 9 states recreationally and 30 states medically. Canada will only be the second country in the world to legalize recreational cannabis nationwide after Uruguay.

Canadian Cannabis M&A Activity

To date, the Cannabis Pharma Sector has been a growing and highly active market. According to a report published by Price Waterhouse Coopers, Canadian merger and acquisition activity in the first half of 2018 has already reached up to $93 billion CAD with this number projected to continually grow by the end of the year.

Large Pharmaceutical companies are developing innovative CBD treatments in various delivery forms. GW Pharmaceuticals Epidiolex is a CBD drug currently in development concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms.

Zynerba has a CBD "Patch" to treat refractory epilepsy, osteoarthritis, PTSD, and cancer-related pain. Axim Biotechnologies have CBD-based chewing gums to treat spasticity and pain related to multiple sclerosis, irritable bowel syndrome, ADHD, ulcerative colitis and Crohn's disease. Insys Therapeutics has a sublingual CBD spray for a variety of pediatric epilepsies including Dravet Syndrome, infantile spasms, and Lennox-Gastaut Syndrome.

Medical Cannabis Market Opportunity

The Medical Marijuana industry is rapidly growing. Currently the market is valued at $14.3B USD. It is estimated to reach a market value of $74.3B USD by 2027 at a projected CAGR of 17.9% from 2017 to 2027. Already over 1.2 million people use Medical Marijuana for medical problems.

Growth for its use is underpinned by numerous factors such as legislation permitting its use for medicinal benefits. Increasing research in the medical field has shown marijuana's benefits in suppressing vomiting and nausea, pain relief, whilst also generating a growing number therapeutic applications for inflammation, HIV/AIDs, cancer, multiple sclerosis, epilepsy, Huntington's disease and Parkinson's disease.

Alexander Somjen, President and CEO of Resinco, said, "The Cannabis Pharma sector is poised for explosive growth.  Gaining an appropriate foothold will enable us to unlock tremendous value for our shareholders. We are looking forward to exploring numerous opportunities in this space."

On behalf of the Board of Directors

RESINCO CAPITAL PARTNERS INC.:

Mr. Alexander Somjen, CEO

For more information, please contact
Theo van der Linde-  604.336.3196

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed "forward-looking statements". The use of any of the words "anticipate", "continue", "estimate", "expect","may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com